Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Nursing Care of Cancer-Related Fatigue

May 1, 2016
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

In this video Alexis Covert, BSN, RN, OCN, discusses a study that aimed to raise awareness among staff nurses on the assessment of cancer-related fatigue, a prevalent and distressing cancer symptoms that affects 80% to 100% cancer patients, and interventions to help treat it.

In this video Alexis Covert, BSN, RN, OCN, of the James Cancer Hospital in Ohio, discusses a study that aimed to raise awareness among staff nurses on the assessment of cancer-related fatigue, a prevalent and distressing cancer symptoms that affects 80% to 100% cancer patients, and interventions to help treat it.

Please note: Due to technical difficulties with the audio during the shooting of this video, we’ve provided a transcript of the discussion below.

Hi, I’m Alexis Covert, I’m a nurse manager at the James Cancer Hospital. My poster is on the nursing care of cancer-related fatigue. We decided to focus on this because we found that up to 80% of our patients are experiencing fatigue, and we were not doing as much as we could to help them.

We were amazed to find that the research showed that patients experienced cancer-related fatigue and these manifestations affect every aspect of their life-not just physically, but mentally, financially. We really wanted to dive in and see what we could do to help them.

Some areas that we focused on were nutrition, anemia, and just their everyday routine and what they can do to improve their life. These include distractions, avoiding caffeine, maintaining a sleep-wake cycle-things that really aren’t that complex but will make a huge difference in their life.

One of the main things they can do is exercise. That was the only evidence-based thing that was proven to assist with cancer-related fatigue. We found there were a lot of barriers-patients are kind of intimidated, or might be post-op and still feeling fatigue so they’re not sure what their physical level is. Or they’re intimidated to do it on their own.

At the James we have “JamesCare for Life,” a facility that helps our patients. We had a survivor come and talk and she does swims and group yoga, and she said that makes a tremendous difference in her life.

We’re also working to educate our staff-our goal is to get 70% of our staff educated on how to assess cancer-related fatigue and what interventions they can do to help their patients.

Recent Videos
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
Advertisement

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Ashley Chan
June 5th 2025
Article

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Related Content
Advertisement

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.


Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Ashley Chan
June 5th 2025
Article

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.